Google Verily deepens the medical and health field and joins Sanofi joint venture to fight type 2 diabetes
Recently, Google's life science company Verily and the well-known diabetes drug manufacturer Sanofi (Sanofi) jointly established a new company, Onduo, to jointly develop products for type 2 diabetes. Among them, Sanofi contributed 248 million US dollars in cash, accounting for 50% of the shares, and Verily will also contribute the same amount (non-cash form). It is understood that as a healthy digital platform, Onduo plans to integrate equipment, software, drugs and services, and hopes to use technology to bring innovative treatment to diabetic patients, in the field of diabetes monitoring and treatment, and patient behavior research. Get a breakthrough. Onduo CEO Joshua Riff has extensive experience at Johns Hopkins Hospital, Optum, and Target. What type of products will Onduo develop? Joshua Riff, CEO of the company, said: "Because we haven't sorted out the specific problems of diabetes, the operation mode of the new platform and the specific development products, there is still no more detailed planning. But what is certain is that unlike the current The research goal of traditional type 2 diabetes always has a clear clinical treatment tendency, such as how to prevent the risk of amputation and blindness. Onduo's approach is to study feasible behaviors and lifestyle changes, improve drug management, and improve patients' living habits. Goals, such as healthy daily routines and diet planning, to control changes in blood sugar, rather than traditional titrations, or constantly changing new drugs." Fighting for diabetes In fact, as early as August last year, Verily cooperated with Sanofi on diabetes testing and treatment projects. The two sides can complement each other to a certain extent: Verily has a certain accumulation in microelectronics, data analysis, software development, and Sanofi has a wealth of medical clinical knowledge and experience. This cooperation, for Sanofi, the timing is just right. As the market's demand for Sanofi's best-selling drug, Lantus, decreased, the company cut its three-year sales forecast last year and began re-planning its diabetes business. At present, Sanofi is making up for the reduction in revenue brought by Lantus by leading the new Toujeo insulin. It is hoped that this cooperation will improve the sales decline caused by the continuous price pressure from the US medical market. Diabetes is a common chronic disease worldwide. There are nearly 400 million people with diabetes in the world. Among them, type 2 diabetes (adult-onset diabetes, usually 35 to 40 years old) accounts for more than 90% of patients. Without a healthy lifestyle and the right treatment options, the number of patients is expected to increase significantly in the coming years. There are many types of companies currently treating diabetes on the market. There are Omada Health, Welldoc, MySugr, Glooko and Livongo with a focus on pre-management. Even device manufacturer Medtronic has partnered with IBM to develop a digital health management app that collects insulin pump data to help patients better regulate their lifestyles. In addition, artificial pancreas is also the main direction of many companies. Startups Beta Bionics, Bigfoot Medical and established companies Insulet, Johnson & Johnson and Medtronic are leaders in this area. Strong enemies, Onduo does not feel a lot of pressure. Riff emphasizes that even with an artificial pancreas, if there is no reasonable diet and lifestyle, patients can't keep their blood sugar stable for a long time without following the doctor's advice, which is what Onduo is trying to solve. Sanofi and Verily will focus on improving medication management and patient habits in order to achieve a win-win situation in terms of blood glucose control and cost reduction. Verily origin and vision Verily was renamed by Google's Life Sciences Research Department. It used to be part of Google X. Verily was founded (renamed) in July 2015. In Middle English, Verily stands for "real, real". In the Alphabet (Google parent company) strategy has the meaning of the "moon landing" program. Core members include CEO Andy Conrad, Ph.D., CTO Brian Otis, Ph.D., CMO Jessica Mega, MD, MPH, Engineering Director Linus Upson, Software Director Tom Stanis, and Science Director Vikram (Vik) Bajaj, Ph .D. et al. Although Alphabet's biggest revenue still comes from Google's core business, like DeepMind, Verily and so on carry this greater intention to improve human life. On Verily's official website, the company's vision is a simple but grand statement: how to use technology to draw a blueprint for human health! The strategic layout and division of Alphabet Organic Corn Resistant Dextrin Powder Resistant Corn Dextrin,Resistant Dextrin Fiber,Dietary Soluble Corn Fiber,Soluble Corn Fiber Shandong Bailong Chuangyuan Bio-tech Co.,Ltd. Qingdao Branch , https://www.sdblcycn.com.jpg)
.jpg)